A Phase 2 Study of Magrolimab and Pembrolizumab in Relapsed or Refractory Classic Hodgkin Lymphoma
Latest Information Update: 24 Jun 2024
At a glance
- Drugs Magrolimab (Primary) ; Pembrolizumab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- 19 Jun 2024 Status changed from suspended to active, no longer recruiting.
- 24 May 2024 Status changed from recruiting to suspended because of the partial clinical hold placed by FDA on all clinical studies of Magrolimab.
- 21 Jun 2022 Status changed from not yet recruiting to recruiting.